BioCentury | Apr 3, 2021
Deals

April 2 Quick Takes: Agios begins share buybacks upon closing Servier deal, plus Royalty-GSK, Gracell-Lonza, Alloy, Eloxx-Zikani and Angelini-Ovid

...to repurchase up to $1.2 billion in outstanding shares over the next 12-18 months.Royalty buys GSK's...
...a royalty interest in Cabometyx cabozantinib, which is also marketed as Cometriq, from GlaxoSmithKline plc (LSE:GSK; NYSE:GSK...
...receive GSK's share of net ex-U.S. sales through the full term of the royalties and GSK's...
BioCentury | Apr 1, 2021
Product Development

COVID roundup: BioNTech-Pfizer vaccine protects adolescents; plus AZ, GSK-Novavax and Amazon

...the vaccine by age and sex in the Canadian context.” GSK to support Novavax vaccine manufacturingSeparately, GSK ...
...Inc. (NASDAQ:NVAX) to support manufacturing of up to 60 million doses of COVID-19 vaccine NVX-2373. GSK...
...tests. BC Staff COVID-19 Vaccine (AZD1222, ChAdOx1 nCoV-19) NVX-CoV2373 Covid 19 Vx, Comirnaty, Pfizer-BioNTech COVID-19 Vaccine (PF-07302048, BNT162, BNT162b2) AstraZeneca plc GlaxoSmithKline plc Novavax...
BioCentury | Apr 1, 2021
Product Development

Lilly-Vir mAb cocktail could expand treatment to low-risk COVID-19 patients

...NASDAQ:REGN).None of those EUAs cover low-risk patients. Lilly, Vir Biotechnology Inc. (NASDAQ:VIR), and Vir partner GlaxoSmithKline plc (LSE:GSK; NYSE:GSK...
...submissions for the combination with FDA and regulators in other countries.Lilly partnered with Vir and GSK...
...data from the Phase II/III COMET-ICE study. Sandi Wong bamlanivimab, LY-CoV555 (LY3819253) VIR-7831 (GSK4182136) Vir Biotechnology Inc. Eli Lilly and Co. GlaxoSmithKline plc AbCellera...
BioCentury | Mar 27, 2021
Regulation

FDA approval solidifies bluebird’s anti-BCMA CAR T as ‘cornerstone’ of BMS’s multiple myeloma portfolio

...delay opened the door for GlaxoSmithKline plc (LSE:GSK; NYSE:GSK...
...line in August. The FDA label for GSK’s...
...maraleucel, (JCAR017) bb21217 Ciltacabtagene autoleucel (JNJ-68284528, JNJ-4528, LCAR-B38M) bluebird bio Inc. GlaxoSmithKline plc Bristol...
BioCentury | Mar 27, 2021
Product Development

A Vir’s-eye view of the path forward for its COVID mAbs

...risk is particularly acute for monotherapies like VIR-7831, for which Vir and partner GlaxoSmithKline plc (LSE:GSK; NYSE:GSK...
...VIR-7831 could serve both as a standalone therapy, and as a backbone for combinations. Vir and GSK...
...will provide protection for three to six months. To get VIR-7831 out of infusion centers, Vir and GSK’s...
BioCentury | Mar 26, 2021
Product Development

Next-generation checkpoint development surges as rare wins overshadow setbacks

...have been quietly discontinued.For example, GlaxoSmithKline plc (LSE:GSK; NYSE:GSK...
BioCentury | Mar 26, 2021
Regulation

CHMP backs GSK’s lupus drug for kidney complication, J&J’s oral MS therapy

...By Sandi Wong, Assistant Editor GSK’s Benlysta and J&J’s Ponvory are two of the latest therapies to win...
...of systemic lupus erythematosus (SLE), in combination with background immunosuppression. The mAb against BlyS from GlaxoSmithKline plc (LSE:GSK; NYSE:GSK...
...agonist, Sphingosine 1-phospate 1 receptor agonist) Benlysta, belimumab (GSK1550188, lymphostat-b, IV Benlysta) Copiktra, duvelisib (IPI-145, ink-1197) CT-P59 Johnson & Johnson GlaxoSmithKline plc Verastem...
BioCentury | Mar 26, 2021
Deals

AllianThera emerges with Insilico deal, team of pharma vets

...Javier Cote-Sierra, whose pedigree includes leadership roles at Sanofi (Euronext:SAN; NASDAQ:SNY), Pfizer and GlaxoSmithKline plc (LSE:GSK; NYSE:GSK). Ding...
BioCentury | Mar 25, 2021
Management Tracks

Slaoui stepping back from all biopharma roles, expresses ‘deep regrets’ following sexual harassment claim

...as Galvani’s chairman by GSK due to sexual harassment allegations. Slaoui, a 30-year veteran of GlaxoSmithKline plc (LSE:GSK; NYSE:GSK...
...Slaoui was an employee of the pharma, according to GSK. Galvani is a JV between GSK...
...time.”Walmsley said GSK will rename Slaoui Center for Vaccine Research in Rockville, Md.The response by GSK’s...
BioCentury | Mar 25, 2021
Product Development

Crucell veterans launch Leyden Labs with €40M to take antiviral nasal sprays toward clinic

...at the the National Institute of Allergy and Infectious Diseases (NIAID); and former GlaxoSmithKline plc (LSE:GSK; NYSE:GSK...
Items per page:
1 - 10 of 9156
BioCentury | Apr 3, 2021
Deals

April 2 Quick Takes: Agios begins share buybacks upon closing Servier deal, plus Royalty-GSK, Gracell-Lonza, Alloy, Eloxx-Zikani and Angelini-Ovid

...to repurchase up to $1.2 billion in outstanding shares over the next 12-18 months.Royalty buys GSK's...
...a royalty interest in Cabometyx cabozantinib, which is also marketed as Cometriq, from GlaxoSmithKline plc (LSE:GSK; NYSE:GSK...
...receive GSK's share of net ex-U.S. sales through the full term of the royalties and GSK's...
BioCentury | Apr 1, 2021
Product Development

COVID roundup: BioNTech-Pfizer vaccine protects adolescents; plus AZ, GSK-Novavax and Amazon

...the vaccine by age and sex in the Canadian context.” GSK to support Novavax vaccine manufacturingSeparately, GSK ...
...Inc. (NASDAQ:NVAX) to support manufacturing of up to 60 million doses of COVID-19 vaccine NVX-2373. GSK...
...tests. BC Staff COVID-19 Vaccine (AZD1222, ChAdOx1 nCoV-19) NVX-CoV2373 Covid 19 Vx, Comirnaty, Pfizer-BioNTech COVID-19 Vaccine (PF-07302048, BNT162, BNT162b2) AstraZeneca plc GlaxoSmithKline plc Novavax...
BioCentury | Apr 1, 2021
Product Development

Lilly-Vir mAb cocktail could expand treatment to low-risk COVID-19 patients

...NASDAQ:REGN).None of those EUAs cover low-risk patients. Lilly, Vir Biotechnology Inc. (NASDAQ:VIR), and Vir partner GlaxoSmithKline plc (LSE:GSK; NYSE:GSK...
...submissions for the combination with FDA and regulators in other countries.Lilly partnered with Vir and GSK...
...data from the Phase II/III COMET-ICE study. Sandi Wong bamlanivimab, LY-CoV555 (LY3819253) VIR-7831 (GSK4182136) Vir Biotechnology Inc. Eli Lilly and Co. GlaxoSmithKline plc AbCellera...
BioCentury | Mar 27, 2021
Regulation

FDA approval solidifies bluebird’s anti-BCMA CAR T as ‘cornerstone’ of BMS’s multiple myeloma portfolio

...delay opened the door for GlaxoSmithKline plc (LSE:GSK; NYSE:GSK...
...line in August. The FDA label for GSK’s...
...maraleucel, (JCAR017) bb21217 Ciltacabtagene autoleucel (JNJ-68284528, JNJ-4528, LCAR-B38M) bluebird bio Inc. GlaxoSmithKline plc Bristol...
BioCentury | Mar 27, 2021
Product Development

A Vir’s-eye view of the path forward for its COVID mAbs

...risk is particularly acute for monotherapies like VIR-7831, for which Vir and partner GlaxoSmithKline plc (LSE:GSK; NYSE:GSK...
...VIR-7831 could serve both as a standalone therapy, and as a backbone for combinations. Vir and GSK...
...will provide protection for three to six months. To get VIR-7831 out of infusion centers, Vir and GSK’s...
BioCentury | Mar 26, 2021
Product Development

Next-generation checkpoint development surges as rare wins overshadow setbacks

...have been quietly discontinued.For example, GlaxoSmithKline plc (LSE:GSK; NYSE:GSK...
BioCentury | Mar 26, 2021
Regulation

CHMP backs GSK’s lupus drug for kidney complication, J&J’s oral MS therapy

...By Sandi Wong, Assistant Editor GSK’s Benlysta and J&J’s Ponvory are two of the latest therapies to win...
...of systemic lupus erythematosus (SLE), in combination with background immunosuppression. The mAb against BlyS from GlaxoSmithKline plc (LSE:GSK; NYSE:GSK...
...agonist, Sphingosine 1-phospate 1 receptor agonist) Benlysta, belimumab (GSK1550188, lymphostat-b, IV Benlysta) Copiktra, duvelisib (IPI-145, ink-1197) CT-P59 Johnson & Johnson GlaxoSmithKline plc Verastem...
BioCentury | Mar 26, 2021
Deals

AllianThera emerges with Insilico deal, team of pharma vets

...Javier Cote-Sierra, whose pedigree includes leadership roles at Sanofi (Euronext:SAN; NASDAQ:SNY), Pfizer and GlaxoSmithKline plc (LSE:GSK; NYSE:GSK). Ding...
BioCentury | Mar 25, 2021
Management Tracks

Slaoui stepping back from all biopharma roles, expresses ‘deep regrets’ following sexual harassment claim

...as Galvani’s chairman by GSK due to sexual harassment allegations. Slaoui, a 30-year veteran of GlaxoSmithKline plc (LSE:GSK; NYSE:GSK...
...Slaoui was an employee of the pharma, according to GSK. Galvani is a JV between GSK...
...time.”Walmsley said GSK will rename Slaoui Center for Vaccine Research in Rockville, Md.The response by GSK’s...
BioCentury | Mar 25, 2021
Product Development

Crucell veterans launch Leyden Labs with €40M to take antiviral nasal sprays toward clinic

...at the the National Institute of Allergy and Infectious Diseases (NIAID); and former GlaxoSmithKline plc (LSE:GSK; NYSE:GSK...
Items per page:
1 - 10 of 9156